Supply of the product Ovestin by Merck Sharp & Dohme

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This Act was introduced to address the problem of ensuring that therapeutic goods available in the market meet certain standards of quality and safety. Enacted by the Commonwealth Parliament, the Act aims to protect public health by controlling the importation, supply, and advertising of therapeutic goods. In this instance, the Act was used to address a specific issue regarding the microbiological standards of a medicinal product, ensuring that it complies with the required efficacy of antimicrobial preservation tests. The Act empowers the Secretary of the Department of Health to grant consent for the supply of therapeutic goods that do not fully conform to certain standards, provided that specific conditions are met to ensure public safety.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, including medicines, medical devices, blood and blood components, tissues, and organs, ensuring their safety, quality, and efficacy. The Act applies to any person or entity involved in the supply, importation, and manufacture of these goods within Australia, thereby establishing a comprehensive regulatory framework across the Commonwealth. Under Sections 14 and 14A, the Act allows the delegate of the Secretary to provide consent for certain therapeutic goods that do not fully comply with specific standards, provided certain conditions are met. This particular consent, granted to Merck Sharp & Dohme Australia Pty Ltd, pertains to the supply of oestriol (OVESTIN) 1 mg/g cream, which did not meet the microbiological standards for medicines as outlined in the Therapeutic Goods Order No. 77. The consent is subject to conditions that ensure the product's ongoing compliance with all other applicable standards and that no other changes are made to the product. The Act's reach is national, applying uniformly across all states and territories of Australia.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 (the Act) empower the delegate of the Secretary of the Department of Health to grant consent for the supply of therapeutic goods that do not fully comply with specified standards. In this instance, Section 14A allows for the supply of oestriol (OVESTIN) 1 mg/g cream tube [Aust R 14515] by Merck Sharp & Dohme Australia Pty Ltd, despite it not meeting the microbiological standards outlined in Section 8 of the Therapeutic Goods Order No. 77—Microbiological standards for medicines. Specifically, the product does not comply with the requirements for A.niger (A. brasiliensis) according to the British Pharmacopoeia Efficacy of Antimicrobial Preservation test. The obligations imposed by this consent are quite specific. The delegate’s consent is ongoing and conditional upon the company adhering strictly to the terms set forth. Notably, no other changes should be made to the product, and all other requirements of Therapeutic Goods Order No. 77 must continue to be met. This ensures that while the particular non-compliance regarding A.niger (A. brasiliensis) is permitted under these circumstances, all other safety and quality standards remain uncompromised. The Therapeutic Goods Act 1989 delineates various offences and penalties for breaches of its provisions, and these extend to any non-compliance not authorised by the Secretary’s delegate. Any deviation from the conditions set by the consent, such as altering the product in any way other than as permitted, could result in enforcement actions. The severity of these actions may include fines, product recalls, and potential legal proceedings. The exact penalties are not specified in the consent itself but are generally detailed within the broader framework of the Act, where contraventions can lead to substantial fines and even imprisonment for serious offences. The Act also provides for civil and criminal liability for non-compliance, ensuring that both the company and any responsible individuals could face consequences. Civil penalties might involve fines up to a significant amount, depending on the severity and impact of the non-compliance. Criminal penalties could include imprisonment, particularly if the non-compliance results in serious harm or endangers public health. Given the sensitive nature of therapeutic goods, these provisions are crucial in maintaining the integrity and safety of products supplied to the Australian market.